New Ashwagandha Research: Should You Worry About Liver Safety?

Ashwagandha is one of the best-selling supplements in the country, and in 2026 it's also become one of the most scrutinized. Two very different bodies of research landed this year: a large government-backed trial that found no liver toxicity, and a growing stack of case reports tying the herb to real liver injury. Both are true at once, and if you're taking ashwagandha — or thinking about starting — you should understand why.

Quick answer: Ashwagandha liver safety isn't a yes-or-no question. The largest trial to date (1,200 people, 24 weeks, one standardized extract) found no liver toxicity. But a real, if small, stack of case reports links the supplement to liver injury, concentrated in people using non-standardized products or already carrying liver risk factors.

What Happened

A scoping review published in 2026 pulled together 13 studies covering 25 documented cases of ashwagandha-associated liver injury, with jaundice and itching (pruritus) as the most common symptoms and elevated bilirubin, AST, and ALT on bloodwork (PubMed; PMC). A separate systematic review found a similar pattern across 19 studies and 26 patients, with liver damage showing up as hepatocellular, cholestatic, or mixed-pattern depending on the case.

At the same time, a large clinical trial backed by India's Ministry of Ayush — 1,200 vaccinated adults across seven centers, dosed daily for 24 weeks with a standardized root extract — reported no treatment-related liver or kidney injury (Herbal Reality, 2026 safety update; BusinessToday coverage). That's the largest ashwagandha safety dataset published to date, and it came back clean.

So the honest summary: the case report literature keeps growing, but the best-designed, largest trial we have shows no signal of harm at studied doses. For a broader look at ashwagandha's evidence base outside of this specific safety question, Examine.com's ashwagandha research summary is a solid independent reference.

Why It Matters

Case reports and randomized trials answer different questions, and the gap between them is exactly what's confusing people right now.

Case reports flag that liver injury can happen — valuable early-warning signals, but with no denominator, they can't tell you how common it is. Millions of people take ashwagandha; a few dozen documented cases globally is a real signal worth taking seriously, not evidence the herb is broadly unsafe.

The 1,200-person trial is the opposite: it's designed to estimate risk in a defined population, and it found none at the doses and duration tested. But it used one standardized, well-characterized extract — not the patchwork of ashwagandha products sold in the U.S., where extraction methods, withanolide concentration, and quality control vary enormously between brands. That patchwork is exactly the gap changing FDA supplement rules are trying to close.

That variability is likely a bigger part of the story than ashwagandha itself. Several of the case reports flagged products with unclear sourcing or non-standardized extracts — exactly the kind of thing third-party testing and standardized extracts like KSM-66 are meant to control for.

The Freak Take

We're not going to tell you ashwagandha is dangerous, or that it's risk-free. Both takes oversell the data.

Here's where we land: this is a supplement with a genuine, if rare, liver injury signal — published case reports in real journals, not a fringe theory. At the same time, the largest, best-controlled safety trial to date found nothing. That combination points toward product quality and individual susceptibility, not a blanket "ashwagandha causes liver damage" conclusion.

If you've got any history of liver disease, drink heavily, or take other medications processed by the liver, this is a legitimate reason to talk to a doctor before adding ashwagandha — not a reason to panic if you've already been taking it without issues.

We continue to recommend standardized, third-party-tested extracts like KSM-66 over generic "ashwagandha root powder" blends with no disclosed extraction method or withanolide percentage — see our KSM-66 vs. Sensoril breakdown if you're deciding between the two major standardized extracts. It's the same logic we apply everywhere: quality control lowers the odds you're the unlucky case report.

What This Means for You

• If you're currently taking ashwagandha and feel fine: the evidence doesn't suggest you need to stop. Liver injury cases remain rare relative to how widely the herb is used.
• Watch for warning signs: yellowing skin or eyes (jaundice), dark urine, persistent itching, unusual fatigue, or abdominal pain. Stop taking it and see a doctor if any of these show up.
• Choose standardized extracts. KSM-66 Ashwagandha uses a full-spectrum root extract with a disclosed withanolide percentage (5%) and third-party testing — the opposite of the unlabeled blends implicated in several case reports. See our full Nootropics Depot KSM-66 review for dosing and label details.
• Don't stack it indefinitely without a break. Most studies test 8-12 week windows. Cycling off periodically isn't strictly required by the evidence, but it's a reasonable, low-cost precaution while more long-term data comes in.
• If you have liver disease, drink heavily, or take hepatotoxic medications, check with your doctor before starting — this is the group where the case reports matter most.
• Check for recalls too. Liver injury isn't the only quality issue that's surfaced this year — see our guide to checking supplement recalls to confirm your specific product hasn't been flagged.

For more on dosing and evidence levels, see our ashwagandha benefits and dosage guide.

The Bottom Line

The largest ashwagandha safety trial to date (1,200 people, 24 weeks) found no liver toxicity, but a real — if small — stack of case reports links the herb to liver injury, especially with poorly standardized products. Choose a third-party-tested, standardized extract, know the warning signs, and check with a doctor if you have existing liver risk factors.

FAQ

Does ashwagandha cause liver damage? Rarely, based on current evidence. A 2026 scoping review found 25 documented case reports of liver injury linked to ashwagandha use, while the largest controlled trial to date (1,200 people, 24 weeks) found no liver toxicity. The injury cases appear uncommon relative to how widely the supplement is used.

Is KSM-66 safer than regular ashwagandha powder? KSM-66 is a standardized, full-spectrum extract with a disclosed withanolide concentration and third-party testing, which reduces the product-quality variability that several liver injury case reports flagged as a contributing factor. It isn't a guarantee against all risk, but it removes one major variable.

What are the warning signs of ashwagandha-related liver injury? Jaundice (yellowing skin or eyes), dark urine, persistent itching, unusual fatigue, and abdominal pain were the most common symptoms across case reports. Stop taking the supplement and see a doctor if any of these appear.

Who should avoid ashwagandha because of liver concerns? People with existing liver disease, heavy alcohol use, or those taking other medications metabolized by the liver should talk to a doctor before starting ashwagandha, since these are the groups where case reports of injury have concentrated.